TGTX
USDTG Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$33.070
Máximo
$34.325
Mínimo
$32.772
Volumen
1.47M
Fundamentos de la Empresa
Capitalización de Mercado
5.4B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
2.11M
Bolsa
NCM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49
JP Morgan analyst Eric Joseph maintains TG Therapeutics with a Overweight and raises the price target from $46 to $49.
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and
Acciones Relacionadas
USCB
USCB Financial Holdings Inc.
XBIT
XBiotech Inc.
DCO
Ducommun Incorporated
FATBP
FAT Brands Inc. 8.25% Series B Cumulative Preferred Stock
FULTP
Fulton Financial Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.